Evaxion A (EVAX) Shares Outstanding (Weighted Average) (2019 - 2026)
Evaxion A (EVAX) reported Shares Outstanding (Weighted Average) of $417.0 billion for Q1 2026, up 50.92% on a YoY basis from $276.3 billion in Q1 2025, and up 2540.81% quarter-over-quarter from $15.8 billion in Q4 2025.
Evaxion A (EVAX) Shares Outstanding (Weighted Average) (2019 - 2026) Analysis & Trends
Evaxion A has reported Shares Outstanding (Weighted Average) for 8 years, with the latest figure at $417.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 50.92% year-over-year to $417.0 billion; the trailing twelve-month figure through Mar 2026 stood at $417.0 billion (up 50.92% YoY), and the FY2025 full-year result was $417.0 million, up 3865.49% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $417.0 billion, up from $15.8 billion in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $417.0 billion in Q1 2026, with the low at $10.0 in Q3 2025.
- Historically, Shares Outstanding (Weighted Average) has averaged $46.6 billion across 5 years, with a median of $3.8 billion in 2022.
- The largest YoY upside for Shares Outstanding (Weighted Average) was 921039756566.67% in 2025 against a maximum downside of 100.0% in 2025.
- Evaxion A's Shares Outstanding (Weighted Average) stood at $23.6 million in 2022, then jumped by 60.32% to $37.9 million in 2023, then plunged by 72.25% to $10.5 million in 2024, then soared by 150061.66% to $15.8 billion in 2025, then surged by 2540.81% to $417.0 billion in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $417.0 billion (Q1 2026), $15.8 billion (Q4 2025), and $10.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 104.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 417.01 Bn |
| Dec 31, 2025 | 15.79 Bn |
| Sep 30, 2025 | 10.00 |
| Jun 30, 2025 | 11.82 Bn |
| Mar 31, 2025 | 276.31 Bn |
| Dec 31, 2024 | 10.52 Mn |
| Sep 30, 2024 | 55.26 Bn |
| Jun 30, 2024 | 120.00 |
| Mar 31, 2024 | 30.00 |
| Dec 31, 2023 | 37.90 Mn |
| Sep 30, 2023 | 4.42 Bn |
| Jun 30, 2023 | 460.00 |
| Mar 31, 2023 | 4.22 Bn |
| Dec 31, 2022 | 23.64 Mn |
| Sep 30, 2022 | 3.86 Bn |
| Jun 30, 2022 | 450.00 |
| Mar 31, 2022 | 3.76 Bn |
| Dec 31, 2021 | 23.20 Mn |
| Sep 30, 2021 | 3.13 Bn |
| Jun 30, 2021 | 3.13 Bn |